Immune Checkpoint Proteins

Immune blockade therapy is becoming a new weapon in oncology due to the development of immune checkpoint proteins targeting in cancer, especially after the success of antibody drugs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).

Although immune checkpoint blockade therapy often leads to a more durable response than chemo or targeted therapies in some cases, clinical data shows a limitation that in most cancers, the response rate is low (10-30%). Therefore, more associated studies focus on the mechanisms of non-responsiveness, as well as developing new targeting strategies using other immune checkpoint proteins.

Utilizing our featured SAMS^TM platform, KACTUS has developed a series of immune checkpoint proteins with multiple pre-labels.